Literature DB >> 2014234

Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules.

P A Roche1, P Cresswell.   

Abstract

HLA-DR molecules are heterodimeric transmembrane glycoproteins that associate intracellularly with a polypeptide known as the invariant (I) chain. Shortly before expression of the HLA-DR alpha beta dimer on the cell surface, however, the I chain is removed from the intracellular alpha beta I complex by a mechanism thought to involve proteolysis. In this report, we show that treatment of purified alpha beta I with the cysteine proteinase cathepsin B results in the specific proteolysis of the HLA-DR-associated I chain in vitro. As a consequence of this, the I chain is removed and free alpha beta dimers are released from alpha beta I. Although alpha beta I fails to bind an immunogenic peptide, the released alpha beta dimers acquire the ability to bind the peptide after proteolysis of the I chain. These results suggest that the I chain inhibits immunogenic peptide binding to alpha beta I early during intracellular transport and demonstrate that proteolysis is likely to be the in vivo mechanism of I chain removal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014234      PMCID: PMC51403          DOI: 10.1073/pnas.88.8.3150

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.

Authors:  L Teyton; D O'Sullivan; P W Dickson; V Lotteau; A Sette; P Fink; P A Peterson
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

Review 2.  Antigen-presenting function of the macrophage.

Authors:  E R Unanue
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

3.  Intracellular class II HLA antigens are accessible to transferrin-neuraminidase conjugates internalized by receptor-mediated endocytosis.

Authors:  P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  Characterization of two distinct DR beta chain alleles at the beta III locus of the DR5 haplotype: beta III alleles are highly conserved.

Authors:  D K Didier; J Schiffenbauer; S Shuman; L F Abruzzini; J Gorski; D L Watling; V L Tieber; B D Schwartz
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

5.  Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene.

Authors:  J S Lee; J Trowsdale; P J Travers; J Carey; F Grosveld; J Jenkins; W F Bodmer
Journal:  Nature       Date:  1982-10-21       Impact factor: 49.962

Review 6.  Cathepsin B, Cathepsin H, and cathepsin L.

Authors:  A J Barrett; H Kirschke
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens.

Authors:  C E Machamer; P Cresswell
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

8.  Invariant chain associates with HLA class II antigens via its extracytoplasmic region.

Authors:  M S Marks; P Cresswell
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

9.  Biosynthetic intermediates of HLA class II antigens from B lymphoblastoid cell lines.

Authors:  D N Kelner; P Cresswell
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

10.  Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells.

Authors:  J Nowell; V Quaranta
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

View more
  70 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.

Authors:  G Guncar; G Pungercic; I Klemencic; V Turk; D Turk
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

3.  The kinetic basis of peptide exchange catalysis by HLA-DM.

Authors:  J A Zarutskie; R Busch; Z Zavala-Ruiz; M Rushe; E D Mellins; L J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

4.  Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.

Authors:  D R Karp; R N Jenkins; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 5.  The expression of HLA-DO (H2-O) in B lymphocytes.

Authors:  Xinjian Chen; Peter E Jensen
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  The endo/lysosomal protease cathepsin B is able to process conalbumin fragments for presentation to T cells.

Authors:  G Gradehandt; E Ruede
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

Review 7.  MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.

Authors:  Toine ten Broeke; Richard Wubbolts; Willem Stoorvogel
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 8.  A peptide's perspective on antigen presentation to the immune system.

Authors:  Jacques Neefjes; Huib Ovaa
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

Review 9.  Selection of the MHC class II-associated peptide repertoire by HLA-DM.

Authors:  S O Arndt; A B Vogt; G J Hämmerling; H Kropshofer
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

10.  Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis.

Authors:  Taejin Yoon; Henriette Macmillan; Sarah E Mortimer; Wei Jiang; Cornelia H Rinderknecht; Lawrence J Stern; Elizabeth D Mellins
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.